flumazenil has been researched along with Huntington Disease in 5 studies
Flumazenil: A potent benzodiazepine receptor antagonist. Since it reverses the sedative and other actions of benzodiazepines, it has been suggested as an antidote to benzodiazepine overdoses.
flumazenil : An organic heterotricyclic compound that is 5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted at positions 3, 5, 6, and 8 by ethoxycarbonyl, methyl, oxo, and fluoro groups, respectively. It is used as an antidote to benzodiazepine overdose.
Huntington Disease: A familial disorder inherited as an autosomal dominant trait and characterized by the onset of progressive CHOREA and DEMENTIA in the fourth or fifth decade of life. Common initial manifestations include paranoia; poor impulse control; DEPRESSION; HALLUCINATIONS; and DELUSIONS. Eventually intellectual impairment; loss of fine motor control; ATHETOSIS; and diffuse chorea involving axial and limb musculature develops, leading to a vegetative state within 10-15 years of disease onset. The juvenile variant has a more fulminant course including SEIZURES; ATAXIA; dementia; and chorea. (From Adams et al., Principles of Neurology, 6th ed, pp1060-4)
Excerpt | Relevance | Reference |
---|---|---|
"Flumazenil Kd was similar in the Huntington's disease group and the control group (11." | 1.31 | Benzodiazepine receptor quantification in Huntington's disease with [(123)I]omazenil and SPECT. ( Hasselbalch, SG; Knudsen, GM; Paulson, OB; Pinborg, LH; Sørensen, SA; Videbaek, C; Wagner, A, 2001) |
"Flumazenil data were analyzed with a recently developed two-compartment, two-parameter tracer kinetic model." | 1.29 | Positron emission tomography measures of benzodiazepine receptors in Huntington's disease. ( Frey, KA; Holthoff, VA; Koeppe, RA; Kuhl, DE; Markel, DS; Penney, JB; Young, AB, 1993) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (40.00) | 18.2507 |
2000's | 3 (60.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Holthoff, VA | 1 |
Koeppe, RA | 1 |
Frey, KA | 2 |
Penney, JB | 1 |
Markel, DS | 1 |
Kuhl, DE | 1 |
Young, AB | 1 |
File, SE | 1 |
Mahal, A | 1 |
Mangiarini, L | 1 |
Bates, GP | 1 |
Künig, G | 1 |
Leenders, KL | 1 |
Sanchez-Pernaute, R | 1 |
Antonini, A | 1 |
Vontobel, P | 1 |
Verhagen, A | 1 |
Günther, I | 1 |
Pinborg, LH | 1 |
Videbaek, C | 1 |
Hasselbalch, SG | 1 |
Sørensen, SA | 1 |
Wagner, A | 1 |
Paulson, OB | 1 |
Knudsen, GM | 1 |
Suzuki, M | 1 |
Desmond, TJ | 1 |
Albin, RL | 1 |
5 other studies available for flumazenil and Huntington Disease
Article | Year |
---|---|
Positron emission tomography measures of benzodiazepine receptors in Huntington's disease.
Topics: Adult; Analysis of Variance; Brain; Carbon Radioisotopes; Female; Flumazenil; Humans; Huntington Dis | 1993 |
Striking changes in anxiety in Huntington's disease transgenic mice.
Topics: Animals; Anxiety; Exploratory Behavior; Female; Flumazenil; Huntington Disease; Maze Learning; Mice; | 1998 |
Benzodiazepine receptor binding in Huntington's disease: [11C]flumazenil uptake measured using positron emission tomography.
Topics: Adult; Carbon Radioisotopes; Caudate Nucleus; Dopamine Antagonists; Female; Flumazenil; GABA Modulat | 2000 |
Benzodiazepine receptor quantification in Huntington's disease with [(123)I]omazenil and SPECT.
Topics: Adult; Female; Flumazenil; Humans; Huntington Disease; Iodine Radioisotopes; Male; Middle Aged; Rece | 2001 |
Vesicular neurotransmitter transporters in Huntington's disease: initial observations and comparison with traditional synaptic markers.
Topics: Adult; Aged; Aged, 80 and over; Animals; Autoradiography; Carrier Proteins; Choline O-Acetyltransfer | 2001 |